<- Back to digest

JOA - 2026-11-01 - Journal Article

Mixing Components From Different Manufacturers in Total Hip Arthroplasty: An Analysis of the American Joint Replacement Registry.

Kirchner GJ, Zaniletti I, De A, Nikkel LE, Stambough JB

retrospective cohortLOE IIIn = 434,985 (matched: 413,607; mixed: 21,378)Minimum 2 years; exact mean not reported.

Topics

arthroplasty
PMID: 41638519DOI: 10.1016/j.arth.2026.01.071View on PubMed ->

Key Takeaway

Mixing THA components from different manufacturers—now occurring in 17% of cases by 2021—carries no increased risk of all-cause revision (HR 1.0, 95% CI 0.9–1.1) compared to matched-manufacturer constructs.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This AJRR registry study compared revision risk in patients ≥65 undergoing primary THA from 2012–2021 with matched versus mixed manufacturer components. Cause-specific Cox models adjusted for confounders showed no significant difference in all-cause revision, aseptic loosening, infection, instability, or periprosthetic fracture between groups. Mixed-component use rose from <2% in 2012 to nearly 17% in 2021, with the mixed cohort more frequently utilizing dual mobility bearings (27% vs. 7%) and triple-tapered stems (18% vs. 9%).

Key Limitation

Minimum 2-year follow-up captures early failures but is inadequate to assess aseptic loosening, the most common long-term revision indication, which peaks beyond 5 years.

Original Abstract

BACKGROUND

As implants in primary total hip arthroplasty (THA) continue to evolve, surgeons may elect to combine femoral and acetabular components from different manufacturers. However, the prevalence of mixing implants in contemporary hip arthroplasty is unknown, as is the consequence that this may or may not have on implant survival.

METHODS

A nationwide registry was used to select patients 65 years or older who underwent primary THA between 2012 and 2021 and who had a minimum 2-year follow-up to create a retrospective cohort comparison of patients who had matched versus mixed manufacturer components. A total of 434,985 cases were identified [matched: 413,607 (95%), mixed: 21,378 (5%)]. The unadjusted and adjusted risk of all-cause revision, as well as revision for aseptic loosening, infection, instability, and periprosthetic fracture, were modeled with cause-specific Cox models.

RESULTS

Mixing THA components increased over time from less than 2% of cases in 2012 to nearly 17% in 2021 (P < 0.001). The mixed cohort more commonly utilized dual mobility bearings (27%, 4,956 versus 7%, 24,631; P < 0.001) and triple-tapered femoral stem designs (18%, 7,185 versus 9%, 27,987; P < 0.001). After controlling for potential confounding variables, there was no difference between the two groups in terms of all-cause revision (hazard ratio (HR) 1.0, 95% confidence interval (CI) 0.9 to 1.1), revision for aseptic loosening (HR 1.2, 95% CI 0.9 to 1.6), revision for infection (HR 1.2, 95% CI 0.9 to 1.4), revision for instability (HR 1.0, 95% CI 0.8 to 1.2), or revision for periprosthetic fracture (HR 0.9, 95% CI 0.7 to 1.2). There was no difference in revision-free survival time between groups.

CONCLUSION

Mixing implants from different manufacturers in primary THA does not result in an associated difference in the risk of early revision between mixed versus matched manufacturer components.